Zydus Cadila’s ZyCov-D vaccine found to be ‘safe and immunogenic’
December 24, 2020
Company wraps up Phase-I/II trials, eyes start of Phase-III
Cadila Healthcare Ltd (Zydus Cadila) on Thursday informed that its plasmid DNA vaccine to prevent Covid-19, ZyCoV-D, was found to be safe, well tolerated and immunogenic in the Phase I/II clinical trials.
The company has now sought approval to initiate Phase-III clinical trials in around 30,000 volunteers.
The Phase-II study of ZyCoV-D had been conducted in over 1,000 healthy adult volunteers as part of the adaptive Phase I/II dose escalation, multi-centric, randomised, double-blind placebo controlled study, a statement said here.